Chitosan-alginate scaffold culture system for hepatocellular carcinoma increases malignancy and drug resistance

Pharmaceutical Research

Volumn 27, Issue 9, 2010, Pages 1939-1948

  Leung, Matthew ^a   Kievit, Forrest M ^a   Florczyk, Stephen J ^a   Veiseh, Omid ^a   Wu, Jennifer ^b   Park, James O ^b   Zhang, Miqin ^a  

^a University of Washington   (United States)

^b UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

Author keywords

chitosan; drug resistance; hepatocellular carcinoma in vitro model; scaffolds; tumor microenvironment

Indexed keywords

ALGINIC ACID; BASIC FIBROBLAST GROWTH FACTOR; CHITOSAN; DOXORUBICIN; GLYPICAN 3; GROWTH FACTOR; INTERLEUKIN 8; MATRIGEL; VASCULOTROPIN;

ANGIOGENESIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BIOCOMPATIBILITY; BLOOD VESSEL; CANCER RESISTANCE; CELL FUNCTION; CELL MIGRATION; CELL PROLIFERATION; CELL STRAIN HEPG2; CELL STRUCTURE; CELL VIABILITY; CONCENTRATION RESPONSE; CONTROLLED STUDY; CULTURE MEDIUM; EXTRACELLULAR MATRIX; GROWTH INHIBITION; HISTOLOGY; HUMAN; HUMAN CELL; LD 50; LIVER CELL CARCINOMA; MALE; MOUSE; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; TUMOR GROWTH;

ALGINATES; ANIMALS; ANTINEOPLASTIC AGENTS; BIOCOMPATIBLE MATERIALS; CELL CULTURE TECHNIQUES; CELL LINE, TUMOR; CELL PROLIFERATION; CELL SURVIVAL; CHITOSAN; DOXORUBICIN; DRUG RESISTANCE, NEOPLASM; GLUCURONIC ACID; HEXURONIC ACIDS; HUMANS; LIVER NEOPLASMS, EXPERIMENTAL; MALE; MICE; MICE, NUDE; MICROSCOPY, ELECTRON, SCANNING; NEOVASCULARIZATION, PATHOLOGIC; TISSUE SCAFFOLDS; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 77955466694     PISSN: 07248741     EISSN: 1573904X     Source Type: Journal    
DOI: 10.1007/s11095-010-0198-3     Document Type: Article

References (43)

1. HC Spangenberg R Thimme HE Blum 2009 Targeted therapy for hepatocellular carcinoma Nat Rev Gastroenterol Hepatol 6 423 432 10.1038/nrgastro.2009.86 1:CAS:528:DC%2BD1MXot12ltLs%3D 19488072
2. JM Llovet S Ricci V Mazzaferro P Hilgard E Gane JF Blanc AC de Oliveira A Santoro JL Raoul A Forner M Schwartz C Porta S Zeuzem L Bolondi TF Greten PR Galle JF Seitz I Borbath D Haussinger T Giannaris M Shan M Moscovici D Voliotis J Bruix 2008 Sorafenib in advanced hepatocellular carcinoma N Engl J Med 359 378 390 10.1056/NEJMoa0708857 1:CAS:528:DC%2BD1cXovFWjsL8%3D 18650514
3. KK Frese DA Tuveson 2007 Maximizing mouse cancer models Nat Rev Cancer 7 654 658 10.1038/nrc2192 (Pubitemid 47327410)
4. L Wu Z-Y Tang Y Li 2009 Experimental models of hepatocellular carcinoma: developments and evolution J Cancer Res Clin Oncol 135 969 981 10.1007/s00432-009-0591-7 19399516
5. C Fischbach R Chen T Matsumoto, et al. 2007 Engineering tumors with 3D scaffolds Nat Med 4 855 860 10.1038/nmeth1085 1:CAS:528:DC%2BD2sXhtV2mtr%2FE (Pubitemid 350055585)
6. JL Horning SK Sahoo S Vijayaraghavalu S Dimitrijevic JK Vasir TK Jain AK Panda V Labhasetwar 2008 3-D tumor model for in vitro evaluation of anticancer drugs Mol Pharm 5 849 862 10.1021/mp800047v 1:CAS:528:DC%2BD1cXptlejs7o%3D 18680382
7. K Smalley M Lioni M Herlyn 2006 Life isn't flat: taking cancer biology to the next dimension In Vitro Cell Dev Biol Anim 42 242 247 10.1290/0604027.1 1:CAS:528:DC%2BD28XhtlensL3E 17163781
8. F Xu K Burg 2007 Three-dimensional polymeric systems for cancer cell studies Cytotechnology 54 135 143 10.1007/s10616-007-9065-4 19003005 (Pubitemid 47339778)
9. O Tredan CM Galmarini K Patel IF Tannock 2007 Drug resistance and the solid tumor microenvironment J Natl Cancer Inst Monogr 99 1441 1454 1:CAS:528:DC%2BD2sXht1yltbrO
10. XZ Wu D Chen GR Xie 2006 Extracellular matrix remodeling in hepatocellular carcinoma: effects of soil on seed? Med Hypotheses 66 1115 1120 10.1016/j.mehy.2005.12.043 1:CAS:528:DC%2BD28XivFSis7c%3D 16504415
11. B Desoize J-C Jardillier 2000 Multicellular resistance: a paradigm for clinical resistance? Crit Rev Oncol Hematol 36 193 207 10.1016/S1040-8428(00) 00086-X 1:STN:280:DC%2BD3M%2FotFSjuw%3D%3D 11033306
12. AI Minchinton IF Tannock 2006 Drug penetration in solid tumours Nat Rev Cancer 6 583 592 10.1038/nrc1893 1:CAS:528:DC%2BD28XntFGlu7w%3D 16862189 (Pubitemid 44140857)
13. MB Meads RA Gatenby WS Dalton 2009 Environment-mediated drug resistance: a major contributor to minimal residual disease Nat Rev Cancer 9 665 674 10.1038/nrc2714 1:CAS:528:DC%2BD1MXhtVWhsb%2FP 19693095
14. A Sermeus JP Cosse M Crespin V Mainfroid F de Longueville N Ninane M Raes J Remacle C Michiels 2008 Hypoxia induces protection against etoposide-induced apoptosis: molecular profiling of changes in gene expression and transcription factor activity Mol Cancer 7 27 10.1186/1476-4598-7-27 18366759 (Pubitemid 351594154)
15. AW Lund Y Bl JP Stegemann GE Plopper 2009 The natural and engineered 3D microenvironment as a regulatory cue during stem cell fate determination Tissue Eng B Rev 15 371 380 10.1089/ten.teb.2009.0270
16. Y Zhang M Zhang 2004 Cell growth and function on calcium phosphate reinforced chitosan scaffolds J Mater Sci Mater Med 15 255 260 10.1023/B:JMSM.0000015485.94665.25 1:CAS:528:DC%2BD2cXhtFShsrw%3D 15334997 (Pubitemid 38388823)
17. Y Zhang MQ Zhang 2001 Microstructural and mechanical characterization of chitosan scaffolds reinforced by calcium phosphates J Non-Cryst Solids 282 159 164 10.1016/S0022-3093(01)00345-3 1:CAS:528:DC%2BD3MXislOmsbs%3D (Pubitemid 32335367)
18. Z Li M Zhang 2005 Chitosan-alginate as scaffolding material for cartilage tissue engineering J Biomed Mater Res A 75A 485 493 10.1002/jbm.a.30449 1:CAS:528:DC%2BD2MXhtFKjtrbL (Pubitemid 41463919)
19. Z Li HR Ramay KD Hauch D Xiao M Zhang 2005 Chitosan-alginate hybrid scaffolds for bone tissue engineering Biomaterials 26 3919 3928 10.1016/j.biomaterials.2004.09.062 1:CAS:528:DC%2BD2MXisFWj 15626439 (Pubitemid 40038783)
20. Z Li J Gunn M-H Chen A Cooper M Zhang 2008 On-site alginate gelation for enhanced cell proliferation and uniform distribution in porous scaffolds J Biomed Mater Res A 86A 552 559 10.1002/jbm.a.31596 1:CAS:528: DC%2BD1cXosFWmtb4%3D (Pubitemid 351969654)
21. Z Li M Leung R Hopper R Ellenbogen M Zhang 2010 Feeder-free self-renewal of human embryonic stem cells in 3D porous natural polymer scaffolds Biomaterials 31 404 412 10.1016/j.biomaterials.2009.09.070 1:CAS:528: DC%2BD1MXhsVWnsbvO 19819007
22. Y Chau RF Padera NM Dang R Langer 2006 Antitumor efficacy of a novel polymer-peptide-drug conjugate in human tumor xenograft models Int J Cancer 118 1519 1526 10.1002/ijc.21495 1:CAS:528:DC%2BD28XhslCqsL0%3D 16187287
23. DJJ Waugh C Wilson 2008 The Interleukin-8 pathway in cancer Clin Cancer Res 14 6735 6741 10.1158/1078-0432.CCR-07-4843 1:CAS:528:DC%2BD1cXhtlens7vL 18980965
24. M Presta P Dell'Era S Mitola E Moroni R Ronca M Rusnati 2005 Fibroblast growth factor/fibroblast growth factor receptor system in angiogenesis Cytokine Growth Factor Rev 16 159 178 10.1016/j.cytogfr.2005.01.004 1:CAS:528: DC%2BD2MXjvVOns7c%3D 15863032 (Pubitemid 40616114)
25. RS Kerbel 2008 Tumor angiogenesis N Engl J Med 358 2039 2049 10.1056/NEJMra0706596 1:CAS:528:DC%2BD1cXlsFyrtro%3D 18463380 (Pubitemid 351656458)
26. M Capurro IR Wanless M Sherman G Deboer W Shi E Miyoshi J Filmus 2003 Glypican-3: a novel serum and histochemical marker for hepatocellular carcinoma Gastroenterology 125 89 97 10.1016/S0016-5085(03)00689-9 1:CAS:528: DC%2BD3sXmtVWqtbk%3D 12851874 (Pubitemid 36799110)
27. XY Wang F Degos S Dubois S Tessiore M Allegretta RD Guttmann S Jothy J Belghiti P Bedossa V Paradis 2006 Glypican-3 expression in hepatocellular tumors: diagnostic value for preneoplastic lesions and hepatocellular carcinomas Hum Pathol 37 1435 1441 10.1016/j.humpath.2006.05.016 1:CAS:528: DC%2BD28XhtFSrt7nP 16949914 (Pubitemid 44739946)
28. A Nassar C Cohen MT Siddiqui 2009 Utility of glypican-3 and survivin in differentiating hepatocellular carcinoma from benign and preneoplastic hepatic lesions and metastatic carcinomas in liver fine-needle aspiration biopsies Diagn Cytopathol 37 629 635 10.1002/dc.21075 1:STN:280:DC%2BD1MrntVSrsw%3D%3D 19405109
29. Hodgson E. A textbook of modern toxicology. 3rd ed: Wiley-Interscience; 2004.
30. R-Z Lin H-Y Chang 2008 Recent advances in three-dimensional multicellular spheroid culture for biomedical research Biotechnol J 3 1172 1184 10.1002/biot.200700228 1:CAS:528:DC%2BD1cXhtlKks7rI 18566957
31. H Shirakawa H Suzuki M Shimomura M Kojima N Gotohda S Takahashi T Nakagohri M Konishi N Kobayashi T Kinoshita T Nakatsura 2009 Glypican-3 expression is correlated with poor prognosis in hepatocellular carcinoma Cancer Sci 100 1403 1407 10.1111/j.1349-7006.2009.01206.x 1:CAS:528:DC%2BD1MXhtVWnsLrJ 19496787
32. J-P Lai DS Sandhu C Yu T Han CD Moser KK Jackson RB Guerrero I Aderca H Isomoto MM Garrity-Park H Zou AM Shire DM Nagorney SO Sanderson AA Adjei J-S Lee SS Thorgeirsson LR Roberts 2008 Sulfatase 2 up-regulates glypican 3, promotes fibroblast growth factor signaling, and decreases survival in hepatocellular carcinoma Hepatology 47 1211 1222 10.1002/hep.22202 1:CAS:528: DC%2BD1cXkslOjs7o%3D 18318435 (Pubitemid 351547907)
33. JA Nagy SH Chang AM Dvorak HF Dvorak 2009 Why are tumour blood vessels abnormal and why is it important to know? Br J Cancer 100 865 869 10.1038/sj.bjc.6604929 1:CAS:528:DC%2BD1MXjt1Gjsbw%3D 19240721
34. B Sangro 2005 Refined tools for the treatment of hepatocellular carcinoma J Hepatol 42 629 631 10.1016/j.jhep.2005.02.006 15826709
35. M Varela MI Real M Burrel A Forner M Sala M Brunet C Ayuso L Castells X Montañá JM Llovet J Bruix 2007 Chemoembolization of hepatocellular carcinoma with drug eluting beads: efficacy and doxorubicin pharmacokinetics J Hepatol 46 474 481 10.1016/j.jhep.2006.10.020 1:CAS:528:DC%2BD2sXhtlCmtb0%3D 17239480 (Pubitemid 46201723)
36. J-J Chuu J Liu M-H Tsou C-L Huang C-P Chen H-S Wang C-T Chen 2007 Effects of paclitaxel and doxorubicin in histocultures of hepatocellular carcinomas J Biomed Sci 14 233 244 10.1007/s11373-006-9141-3 1:CAS:528:DC%2BD2sXmtVyqtrY%3D 17206490 (Pubitemid 46625402)
37. WGEJ Schoonen JADM de Roos WMA Westerink E Débiton 2005 Cytotoxic effects of 110 reference compounds on HepG2 cells and for 60 compounds on HeLa, ECC-1 and CHO cells.: II Mechanistic assays on NAD(P)H, ATP and DNA contents Toxicol In Vitro 19 491 503 10.1016/j.tiv.2005.01.002 1:CAS:528: DC%2BD2MXjtF2jsLs%3D 15826807
38. Hirschhaeuser F, Menne H, Dittfeld C, West J, Mueller-Klieser W, Kunz-Schughart LA. Multicellular tumor spheroids: an underestimated tool is catching up again. J. Biotechnol. 2010; In Press, Corrected Proof.
39. M Hennessy JP Spiers 2007 A primer on the mechanics of P-glycoprotein the multidrug transporter Pharmacol Res 55 1 15 10.1016/j.phrs.2006.10.007 1:CAS:528:DC%2BD2sXntlequg%3D%3D 17095241 (Pubitemid 46108588)
40. Patel K, Tannock I. The influence of P-glycoprotein expression and its inhibitors on the distribution of doxorubicin in breast tumors. 2009. p. 356.
41. BC Baguley 2010 Multidrug resistance in cancer Meth Mol Biol 596 1 14 10.1007/978-1-60761-416-6-1 1:CAS:528:DC%2BC3cXhvVKhtLk%3D
42. A Jurisicova HJ Lee SG D'Estaing J Tilly GI Perez 2006 Molecular requirements for doxorubicin-mediated death in murine oocytes Cell Death Differ 13 1466 1474 10.1038/sj.cdd.4401819 1:CAS:528:DC%2BD28XotVylt7w%3D 16439991 (Pubitemid 44210350)
43. A Wichert A Stege Y Midorikawa PS Holm H Lage 2003 Glypican-3 is involved in cellular protection against mitoxantrone in gastric carcinoma cells Oncogene 23 945 955 10.1038/sj.onc.1207237